U.S. markets open in 9 hours 5 minutes
  • S&P Futures

    3,408.50
    -24.00 (-0.70%)
     
  • Dow Futures

    27,944.00
    -190.00 (-0.68%)
     
  • Nasdaq Futures

    11,619.25
    -72.00 (-0.62%)
     
  • Russell 2000 Futures

    1,591.70
    -11.40 (-0.71%)
     
  • Crude Oil

    39.79
    -0.24 (-0.60%)
     
  • Gold

    1,916.50
    -13.00 (-0.67%)
     
  • Silver

    24.89
    -0.35 (-1.39%)
     
  • EUR/USD

    1.1847
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • Vix

    28.65
    -0.70 (-2.39%)
     
  • GBP/USD

    1.3129
    -0.0015 (-0.11%)
     
  • USD/JPY

    104.7090
    +0.1490 (+0.14%)
     
  • BTC-USD

    12,775.52
    +1,718.51 (+15.54%)
     
  • CMC Crypto 200

    256.11
    +11.22 (+4.58%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,447.02
    -192.44 (-0.81%)
     

Akero Therapeutics IPO Opens Above IPO Price

Tanzeel Akhtar

Akero Therapeutics (NASDAQ: AKRO) shares opened at $16.16 Thursday morning after pricing of 5.75 million shares of common stock at $16.

Akero was founded in January 2017 and focuses on developing transformative treatments for serious metabolic diseases with high unmet medical need, with the accent on non-alcoholic steatohepatitis, or NASH, which currently has no FDA-approved therapies.

Akero's lead candidate AKR-001, an analog of fibroblast growth factor 21, or FGF21, is being evaluated for NASH. FGF21 is a hormone that regulates metabolism of lipids, carbohydrates and proteins and also protects tissues from various forms of stress.

Akero reported a wider loss of $81.71 million for the fiscal year 2018 compared to $4.56 million in 2017. For the three months ended March 2019, the company reported a loss of $5.36 million.

The stock traded around $16.71 per share at time of publication.

Related Links:

Akero Therapeutics IPO: What You Need To Know

IPO Outlook For The Week: Biotechs And A Grocery Outlet

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.